The Latest

  • making a leap
    Image attribution tooltip
    Stock via Getty Images

    Making the leap from the lab to the boardroom

    Four academics-turned-executives share what they’ve learned about the pivot point between life sciences academia and entrepreneurship.

  • Magical, illuminated mushroom growing on a moss
    Image attribution tooltip
    Stock via Getty Images

    ‘The Last of Us’ might be fiction, but fungi are a looming threat

    Fungal infections are a growing challenge for hospitalized patients, and new treatments are badly needed.

  • DNA sequencing gel
    Image attribution tooltip
    Stock via Getty Images
    Biotech Spotlight

    This biotech’s ‘Microsoft’ approach could change how we see gene therapy

    The company’s using a unique component-based platform to develop functional cures for diseases, including HIV.

  • Nobel Peace Prize
    Image attribution tooltip
    Chris Jackson/Getty Images via Getty Images

    A biopharma CEO’s quest for global health equity has put him in the running for a Nobel Prize

    Dr. Ryan Saadi, CEO of Tevogen Bio, is making good on a lifelong goal of bringing T cell therapies to people who need them.

  • A man walks out of the Pfizer world headquarters building.
    Image attribution tooltip
    Chris Hondros / Staff via Getty Images

    Return of the megadeal: Pfizer’s Seagen buy has the industry asking if super-sized M&A is back

    A $43 billion deal that doubles the pharma giant's cancer pipeline shows that M&A is back on the table in pharma.

  • A glass building with a sign that reads, "Biogen."
    Image attribution tooltip

    Paul Marotta/Sipa USA/Newscom

    Making Moves

    In the fallout from Aduhelm, Biogen’s leadership shakeup continues

    The recent departure of neurodegenerative development head Samantha Budd Haeberlein is just the latest sign of a changing tide among Biogen’s post-Aduhelm leadership.

  • leadership
    Image attribution tooltip
    Stock via Getty Images
    PharmaVoice 100

    The PharmaVoice 100 — Who makes the cut

    What we’re looking for in each new class of honorees.

  • Chris Fox Novartis Gene Therapies
    Image attribution tooltip
    Permission granted by Chris Fox Novartis Gene Therapies
    Podcast

    Woman of the Week: Novartis Gene Therapies’ Chris Fox

    Welcome to the Woman of the Week podcast, a weekly discussion that illuminates the unique stories of women leaders who are catalyzing change throughout the life sciences industry. You can check out all our podcast episodes here. When Novartis acquired AveXis and its spinal muscular atroph...

  • Christiane Langer
    Image attribution tooltip
    Permission granted by BeiGene
    Profile

    A rising oncology powerhouse in China, BeiGene looks to strengthen its international punch

    To expand its reach, Christiane Langer, the company’s head of medical affairs, is leaning on connections and singularity over fitting in a box.

  • hands connecting healthcare
    Image attribution tooltip
    Stock via Getty Images
    Profile

    The power of connections for a startup CEO

    Priyanka Dutta-Passecker, head of wound-care specialist Healiva, discusses the importance of tapping her network in starting and running a biotech.

  • U.S. President Joe Biden speaking in Philadelphia.
    Image attribution tooltip
    Chip Somodevilla/Staff/Getty Images News via Getty Images

    Biden doubles down on drug pricing in 2024 budget — but boosts R&D

    The president’s 2024 budget proposal expands on last year’s drug pricing reforms, but also dramatically increases innovation investments.

  • Babson Diagnostics
    Image attribution tooltip
    Permission granted by Babson Diagnostics
    Q&A

    Babson aims to shed Theranos curse with new blood testing tech

    Babson Diagnostics is trying to create a less invasive blood testing technology — can it gain trust in the post-Theranos era?

  • Murray Aitken IQVIA Institute
    Image attribution tooltip
    Permission granted by Murray Aitken/IQVIA Institute
    Q&A

    IQVIA’s OG of data analytics on the latest clinical trial trends

    IQVIA Institute’s Murray Aitken is the man behind the numbers, and here, shares the newest findings on clinical trial burnout, diversity and more.

  • Cooked vegetables in black plastic containers
    Image attribution tooltip
    Permission granted by Faeth
    Q&A // Biotech Spotlight

    While many leverage precision medicine, Faeth is banking on precision nutrition to tackle cancer

    The San Francisco-based biotech is pairing metabolically-engineered diets with existing therapies to starve and kill tumors.

  • Neuroscience
    Image attribution tooltip
    iStock via Getty Images

    Janssen neuroscience leader takes on rare diseases one small ‘eureka’ at a time

    Fueled by a fascination with the scientific process, Sindhu Ramchandren is exploring how a new drug could treat patients with a range of rare diseases.

  • Senior older women
    Image attribution tooltip
    Stock via Getty Images

    Targeting the new ‘Golden Girls’

    With unprecedented buying power, women over 50 wield a lot of influence — but are still underserved by pharma. Urovant hopes to change that with its potential blockbuster drug.

  • Amy Ripka Lucy Therapeutics
    Image attribution tooltip
    Permission granted by Amy Ripka Lucy Therapeutics
    Podcast

    Woman of the Week: Lucy Therapeutics’ Amy Ripka

    How a 3.2-million-year-old fossil inspired the CEO to unlock the mysteries of mitochondrial dysfunction.

  • Concept image of insulin aspart with fake labeling
    Image attribution tooltip
    Samara Heisz via Getty Images

    Eli Lilly took price cuts into its own hands. Will other pharmas follow suit?

    The pharma giant took the high road and cut prices before the feds made them. How will that affect the industry?

  • storytelling marketing
    Image attribution tooltip
    Stock via Getty Images

    3 keys to good storytelling in pharma

    The CEO of Complement Therapeutics shares simple storytelling tactics lead to maximum impact.

  • layoffs
    Image attribution tooltip
    Stock via Getty Images

    Why layoffs are not the answer to biopharma’s troubled market

    As companies look to cut costs, an EY analyst urges them to consider not cutting staff.

  • Colorful medical pills cover Benjamin Franklin's face on one hundred american dollar bill.
    Image attribution tooltip
    Stock via Getty Images

    FDA ups generics and biosimilar approvals for a shot at lower drug costs

    As the Biden administration searched for drug-cost reducing measures, the FDA incentivized generic and biosimilar development in 2022. 

  • silhouette people
    Image attribution tooltip
    Stock via Getty Images

    PharmaVoice 100 honorees: Where are they now?

    How some of our past PharmaVoice 100 honorees are transforming the life sciences industry in new roles. 

  • Cell therapy DNA
    Image attribution tooltip
    iStock via Getty Images
    Q&A // First 90 Days

    The ‘recovering academic’ leading Allogene to the next stage of cell therapy

    Zachary Roberts joined Allogene at the beginning of this year to lead the company's R&D and bring allogeneic cell therapy to the forefront.

  • A 3D illustration of ribonucleic acid, or RNA, strands
    Image attribution tooltip
    Christoph Burgstedt via Getty Images
    Q&A // Biotech Spotlight

    Launched with a ‘pioneer’ in RNA, aTyr Pharma is charting a new course in immunology

    With a focus on rare and hard-to-treat diseases, aTyr is banking on its head start in tRNA and vast IP portfolio to build a billion-dollar company.

  • pharma lab cropped
    Image attribution tooltip
    Stock via Getty Images

    Do R&D costs justify the price of drugs? Nope, new study says

    A BMJ study found that spending on drug sales vastly outstripped spending on drug development.